- INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
- INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
- INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
- INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
- INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
- INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
- INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
- INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
- INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
More ▼
Key statistics
On Wednesday, INmune Bio Inc (INMB:NAQ) closed at 10.70, -27.41% below its 52-week high of 14.74, set on Feb 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.70 |
---|---|
High | 11.03 |
Low | 10.61 |
Bid | 10.31 |
Offer | 11.20 |
Previous close | 10.56 |
Average volume | 113.58k |
---|---|
Shares outstanding | 19.78m |
Free float | 13.42m |
P/E (TTM) | -- |
Market cap | 208.90m USD |
EPS (TTM) | -1.92 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼